A roundup of exits, including IPOs and acquisitions, across the tech transfer ecosystem.
Rewrite Therapeutics, a US-based DNA writing technologies spinout of University of California, Berkeley, has been acquired by genome editing company Intellia Therapeutics for $45m in an upfront payment and up to an additional $155m in milestone payments through a mix of stock and cash. Rewrite Therapeutics was founded in 2016. It raised $2m in a seed round led by Civilization Ventures and backed by Prefix Capital and Cystic Fibrosis Foundation in September 2021, according to deals database PitchBook.
StreetLight Data,…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
